---
schema_version: "secwatch.filing_event.v1"
accession: "0001711279-26-000008"
form_type: "8-K"
ticker: "KRYS"
cik: "0001711279"
company_name: "Krystal Biotech, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:54:04.029300+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Krystal Biotech pre-announces 2025 VYJUVEK revenue ~$388-389M; outlines 4 product launches by 2030

## Summary
- Preliminary Q4 2025 VYJUVEK net revenue $106-107M; full year $388-389M.
- Cash, equivalents and investments ~$955M as of Dec 31, 2025.
- Targets 4 marketed rare-disease medicines (incl. VYJUVEK) by end of 2030, treating >10,000 patients.
- 2026 combined non-GAAP R&D and SG&A expense guidance $175-195M (excl. stock comp).
- Pipeline milestones: Phase 3 data for KB803 (ocular DEB) and KB801 (NK) in 2026; KB407 CF study enrollment starts.

## SEC filing metadata
- accession: 0001711279-26-000008
- form_type: 8-K
- ticker: KRYS
- cik: 0001711279
- company_name: Krystal Biotech, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711279/000171127926000008/0001711279-26-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711279/000171127926000008/krys-20260111.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001711279-26-000008
- JSON: https://secwatch.observer/filing/0001711279-26-000008.json
- Plain text: https://secwatch.observer/filing/0001711279-26-000008.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.